PL3689906T3 - Przeciwciało przeciwko il-5 lub jego fragment wiążący antygen w zastosowaniu medycznym - Google Patents

Przeciwciało przeciwko il-5 lub jego fragment wiążący antygen w zastosowaniu medycznym

Info

Publication number
PL3689906T3
PL3689906T3 PL18860941.6T PL18860941T PL3689906T3 PL 3689906 T3 PL3689906 T3 PL 3689906T3 PL 18860941 T PL18860941 T PL 18860941T PL 3689906 T3 PL3689906 T3 PL 3689906T3
Authority
PL
Poland
Prior art keywords
antibody
antigen binding
binding fragment
medical application
medical
Prior art date
Application number
PL18860941.6T
Other languages
English (en)
Inventor
Hua Ying
Jinping SHI
Yifang Wang
Qiyue Hu
Hu GE
Weikang Tao
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Shanghai Hengrui Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of PL3689906T3 publication Critical patent/PL3689906T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
PL18860941.6T 2017-09-29 2018-09-28 Przeciwciało przeciwko il-5 lub jego fragment wiążący antygen w zastosowaniu medycznym PL3689906T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710906068 2017-09-29
PCT/CN2018/108240 WO2019062831A1 (zh) 2017-09-29 2018-09-28 Il-5抗体、其抗原结合片段及医药用途

Publications (1)

Publication Number Publication Date
PL3689906T3 true PL3689906T3 (pl) 2025-11-24

Family

ID=65900695

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18860941.6T PL3689906T3 (pl) 2017-09-29 2018-09-28 Przeciwciało przeciwko il-5 lub jego fragment wiążący antygen w zastosowaniu medycznym

Country Status (15)

Country Link
US (3) US11365247B2 (pl)
EP (1) EP3689906B1 (pl)
JP (1) JP7307720B2 (pl)
KR (1) KR102709785B1 (pl)
CN (1) CN111065651B (pl)
AU (1) AU2018340557B2 (pl)
BR (1) BR112020005766A2 (pl)
CA (1) CA3076941A1 (pl)
ES (1) ES3046715T3 (pl)
MX (1) MX2020003034A (pl)
MY (1) MY201928A (pl)
PL (1) PL3689906T3 (pl)
TW (1) TWI801425B (pl)
WO (1) WO2019062831A1 (pl)
ZA (1) ZA202001807B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641908B2 (ja) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
CN114075282B (zh) * 2020-08-20 2024-01-02 南京融捷康生物科技有限公司 Il-5的结合分子及其制备方法和应用
US20250051435A1 (en) * 2023-08-11 2025-02-13 Invetx, Inc. Anti-il-5 antibodies and uses thereof
CN121362251A (zh) * 2024-07-19 2026-01-20 普米斯生物技术(珠海)有限公司 抗il-5抗体、其药物组合物及用途
CN120884696A (zh) * 2024-08-23 2025-11-04 深圳瑞思普利生物制药股份有限公司 抗il-5抗体的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
JP2001523083A (ja) 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
KR100509993B1 (ko) * 1994-12-23 2006-02-28 스미스클라인비이참피이엘시이 Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
KR101206318B1 (ko) 2004-10-28 2012-11-29 교와 핫꼬 기린 가부시키가이샤 자궁 내막증 치료제
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
WO2009072660A1 (ja) 2007-12-03 2009-06-11 Kabushiki Kaisya Advance 抗体作製方法
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
WO2012158954A1 (en) 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
BR112016011027A2 (pt) 2013-12-20 2017-12-05 Genentech Inc método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
AU2015315628A1 (en) 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions

Also Published As

Publication number Publication date
CA3076941A1 (en) 2019-04-04
EP3689906A4 (en) 2021-04-07
KR102709785B1 (ko) 2024-09-24
MY201928A (en) 2024-03-24
EP3689906C0 (en) 2025-09-10
BR112020005766A2 (pt) 2020-10-13
ZA202001807B (en) 2022-09-28
EP3689906A1 (en) 2020-08-05
WO2019062831A1 (zh) 2019-04-04
ES3046715T3 (en) 2025-12-02
US11365247B2 (en) 2022-06-21
RU2020112984A (ru) 2021-10-29
KR20200059239A (ko) 2020-05-28
AU2018340557A1 (en) 2020-04-09
TW201915022A (zh) 2019-04-16
US12258394B2 (en) 2025-03-25
EP3689906B1 (en) 2025-09-10
TWI801425B (zh) 2023-05-11
US20250333494A1 (en) 2025-10-30
JP2021502801A (ja) 2021-02-04
US20200262909A1 (en) 2020-08-20
RU2020112984A3 (pl) 2021-11-25
CN111065651A (zh) 2020-04-24
MX2020003034A (es) 2020-07-22
CN111065651B (zh) 2023-07-14
US20220356239A1 (en) 2022-11-10
JP7307720B2 (ja) 2023-07-12
AU2018340557B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
ZA201700528B (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
IL275510A (en) Specific antigen-binding molecules-ROR1
IL268258A (en) CD47 antigen binding unit and uses thereof
ZA202003133B (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
DK3182999T3 (da) Anti-lag3-antistoffer og antigenbindingsfragmenter
ZA201803206B (en) Antibodies and antibody fragments for site-specific conjugation
EP3378871A4 (en) PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF
EP3632932A4 (en) ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE
ZA202001807B (en) Il-5 antibody, antigen binding fragment thereof, and medical application therefor
SMT202200432T1 (it) Anticorpi, frammenti anticorpali anti-ror2, loro immunoconiugati e loro usi
EP3587452A4 (en) ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT
HUE042815T2 (hu) Humán P53 lineáris epitópot kötõ antitest és diagnosztikai alkalmazásai
LT3269735T (lt) Antikūnas prieš sklerostiną, antigeną surišantis fragmentas ir jų medicininis panaudojimas
ZA201906821B (en) Anti-jagged1 antigen binding proteins
GB201415714D0 (en) Antibodies and antigen binding fragments thereof
GB201614627D0 (en) Antigen binding proteins
ZA202001042B (en) Antibody specifically binding to pauf protein, and use thereof
IL261033A (en) Human antibodies and tensin-binding fragments
HK1234073A1 (en) Anti-hepatitis c antibodies and antigen binding fragments thereof